# A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Source: https://onco.cc/trials/nct05302284/  
OnCo record `nct05302284` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Toripalimab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma is a phase 3 interventional study registered as NCT05302284 by RemeGen Co., Ltd., with 452 participants planned, started 2022-06-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: RC48-ADC, Toripalimab, Gemcitabine, Cisplatin and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05302284
- Phase: 3
- Setting: A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 452

## Sources

- ClinicalTrials.gov NCT05302284: https://clinicaltrials.gov/study/NCT05302284

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct05302284.json